Mark A. Miller

26.4k total citations · 4 hit papers
254 papers, 17.1k citations indexed

About

Mark A. Miller is a scholar working on Epidemiology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Mark A. Miller has authored 254 papers receiving a total of 17.1k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Epidemiology, 84 papers in Infectious Diseases and 55 papers in Molecular Biology. Recurrent topics in Mark A. Miller's work include Influenza Virus Research Studies (52 papers), Clostridium difficile and Clostridium perfringens research (46 papers) and COVID-19 epidemiological studies (36 papers). Mark A. Miller is often cited by papers focused on Influenza Virus Research Studies (52 papers), Clostridium difficile and Clostridium perfringens research (46 papers) and COVID-19 epidemiological studies (36 papers). Mark A. Miller collaborates with scholars based in United States, Canada and United Kingdom. Mark A. Miller's co-authors include Cécile Viboud, Lone Simonsen, Thomas Louie, Kathleen M. Mullane, Gerardo Chowell, Sherwood L. Gorbach, André Dascal, Wladimir J. Alonso, Arnold Lentnek and Yoav Golan and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Mark A. Miller

253 papers receiving 16.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile–Associated Diarrhea with High Morbidity and Mortality

2005 1.6k citations Mark A. Miller, Ken Dewar et al. profile →
Fidaxomicin versus Vancomycin for Clostridium difficile Infection

2011 1.1k citations Thomas Louie, Mark A. Miller et al. profile →
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

2011 831 citations Fredrick Van Goor, Sabine Hadidaꝉ et al. Proceedings of the National Academy of Sciences profile →
Severe Respiratory Disease Concurrent with the Circulation of H1N1 Influenza

2009 533 citations Gerardo Chowell, Mark A. Miller et al. profile →

Peers

Countries citing papers authored by Mark A. Miller

Since Specialization

Citations

This map shows the geographic impact of Mark A. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Miller more than expected).

Fields of papers citing papers by Mark A. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Miller. The network helps show where Mark A. Miller may publish in the future.

Co-authorship network of co-authors of Mark A. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Miller. A scholar is included among the top collaborators of Mark A. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Miller. Mark A. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of the Risk Analysis Index and the Modified 5-Item Frailty Index in Predicting 30-Day Morbidity and Mortality After Occipitocervical Fusion 2025 ·Global Spine Journal ·(unknown), Nithin Gupta, (unknown), (unknown), (unknown), Mark A. Miller, Rohin Singh, (unknown), (unknown), (unknown), Jonathan Stone, Christian A. Bowers	0
2	A Practical Approach to Using the Genomic Standards Consortium MIxS Reporting Standard for Comparative Genomics and Metagenomics 2024 ·Methods in molecular biology ·Emiley A. Eloe‐Fadrosh, Chris Mungall, Mark A. Miller, (unknown), (unknown), (unknown), L. Johnson, (unknown), Patrick Chain, Bin Hu, (unknown), Lee Ann McCue, Alice C. McHardy, Nomi L. Harris, T. B. K. Reddy, Supratim Mukherjee, Chris Hunter, Ramona Walls, Lynn M. Schriml	3
3	The Artificial Intelligence Ontology: LLM-Assisted Construction of AI Concept Hierarchies 2024 ·Applied Ontology ·Marcin P. Joachimiak, Mark A. Miller, J. Harry Caufield, Ryan Ly, Nomi L. Harris, Andrew Tritt, Chris Mungall, Kristofer E. Bouchard	1
4	A novel tool for standardizing clinical data in a semantically rich model 2020 ·Journal of Biomedical Informatics ·(unknown), (unknown), Mark A. Miller, David Birtwell, Danielle L. Mowery, Christian J. Stoeckert	7
5	An Automated Assistant for Medical Scribes. 2018 ·Conference of the International Speech Communication Association ·(unknown), Erik Edwards, (unknown), Najmeh Sadoughi, (unknown), Mark A. Miller, David Suendermann‐Oeft, (unknown), (unknown)	5
6	Prevention and treatment of secretory diarrhea by the lysophosphatidic acid analog Rx100 2018 ·Experimental Biology and Medicine ·Karin E. Thompson, Ramesh M. Ray, Shanta Alli, (unknown), (unknown), (unknown), Avtar S. Meena, Pradeep K. Shukla, (unknown), Leonard R. Johnson, Mark A. Miller, Gábor Tigyi	8
7	Transforming and Unifying Research with Biomedical Ontologies: The Penn TURBO Project. 2018 ·Christian J. Stoeckert, David Birtwell, (unknown), Mark A. Miller, (unknown)	1
8	Crowdsourced Continuous Improvement of Medical Speech Recognition. 2017 ·National Conference on Artificial Intelligence ·Wael Salloum, Erik Edwards, Shabnam Ghaffarzadegan, David Suendermann‐Oeft, Mark A. Miller	6
9	Deep Learning for Punctuation Restoration in Medical Reports 2017 ·Wael Salloum, (unknown), Erik Edwards, Mark A. Miller, David Suendermann‐Oeft	17
10	Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection 2016 ·Microbiome ·Caroline Vincent, Mark A. Miller, Thaddeus J. Edens, Sudeep Mehrotra, Ken Dewar, Amee R. Manges	98
11	Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials 2012 ·Clinical Infectious Diseases ·Derrick W. Crook, A. Sarah Walker, Yin Kean, Karl Weiss, Oliver A. Cornely, Mark A. Miller, Roberto Esposito, Thomas Louie, Nicole Stoesser, Bernadette Young, Brian Angus, Sherwood L. Gorbach, Tim Peto	197
12	Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 breakdown → 2011 ·Proceedings of the National Academy of Sciences ·Fredrick Van Goor, Sabine Hadidaꝉ, Peter D. J. Grootenhuis, Bill Burton, Jeffrey H. Stack, Kimberly Straley, Caroline J. Decker, Mark A. Miller, (unknown), Eric R. Olson, Jeffrey J. Wine, (unknown), Melissa A. Ashlock, Paul A. Negulescu	831
13	Characterizing the Epidemiology of the 2009 Influenza A/H1N1 Pandemic in Mexico 2011 ·PLoS Medicine ·Gerardo Chowell, Santiago Echevarría‐Zuno, Cécile Viboud, Lone Simonsen, James Tamerius, Mark A. Miller, Víctor Hugo Borja‐Aburto	193
14	Effect of gastric acid suppressants on human gastric motility 1998 ·Gut ·Henry P. Parkman, (unknown), L C Knight, Kevin L. Brown, (unknown), Mark A. Miller, Alan H. Maurer, Robert S. Fisher	167
15	Managing Internetworks with SNMP; The Definitive Guide to the Simple Network Management Protocal, SNMPV2, RMON, and Rmon2 1997 ·Mark A. Miller, (unknown)	3
16	Development of Mupirocin Resistance Among Methicillin-ResistantStaphylococcus aureusAfter Widespread Use of Nasal Mupirocin Ointment 1996 ·Infection Control and Hospital Epidemiology ·Mark A. Miller, André Dascal, Joseph Portnoy, Jack Mendelson	32
17	Identification of a Calmodulin-Binding and Inhibitory Peptide Domain in the HIV-1 Transmembrane Glycoprotein 1993 ·AIDS Research and Human Retroviruses ·Mark A. Miller, Timothy A. Mietzner, Miles W. Cloyd, W. Gerard Robey, Ronald C. Montelaro	64
18	Identification of Broadly Reactive Continuous Antigenic Determinants of Simian Immunodeficiency Virus Glycoproteins 1992 ·AIDS Research and Human Retroviruses ·Mark A. Miller, Michael Murphey‐Corb, Ronald C. Montelaro	20
19	Risk Factors for the Development of Clostridium difficile -Associated Diarrhea During a Hospital Outbreak 1991 ·Infection Control and Hospital Epidemiology ·Alain Thibault, Mark A. Miller, (unknown)	108
20	A Structural Correlation Between Lentivirus Transmembrane Proteins and Natural Cytolytic Peptides 1991 ·AIDS Research and Human Retroviruses ·Mark A. Miller, Robert F. Garry, Jesse M. Jaynes, Ronald C. Montelaro	92

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact